Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases (GlobeNewswire) - Feb 26, 2025 - P1 | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "Plus Therapeutics, Inc...announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D....Enrollment in Cohort 6 was recently completed (75.0 mCi). The Cohort 4 dose (44.1 mCi) was determined to be the RP2D; no dose-limiting toxicities were observed at this dose level. One patient at the Cohort 4 dose was observed to have achieved a complete response, as evidenced by the eradication of tumor cells in the cerebrospinal fluid—a key therapeutic endpoint."
Enrollment status • P1 data • CNS Tumor
|